RxDoctor Payments Data

Jill Schramm

Adult Health · Aurora, CONPI 1811922396

Payments from drug & device makers

$664in general payments, 2019–2025

Across 23 payments — averaging $28.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$190
  • Novo Nordisk$182
  • Tandem Diabetes Care, Inc.$132
  • AstraZeneca$46
  • BD$25
  • Boston Scientific$24
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$664 in reported general payments places this provider in the 65th percentile of 430 adult health providers in Colorado.

See all adult health providers in Colorado

Medicare billing

Part B allowed, 2024
$25,625
Medicare patients
100
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide83$127,867
OzempicSemaglutide78$115,563
MounjaroTirzepatide79$94,955
JardianceEmpagliflozin38$63,991
Tresiba Flextouch U-100Insulin Degludec43$32,475
FarxigaDapagliflozin Propanediol22$32,473
Humalog Kwikpen U-100Insulin Lispro56$21,752
Lantus SolostarInsulin Glargine,hum.Rec.Anlog121$17,645
Insulin Lispro Kwikpen U-100Insulin Lispro33$8,515
NovologInsulin Aspart20$7,531
Nano 2nd Gen Pen NeedlePen Needle, Diabetic55$5,951
Novolog FlexpenInsulin Aspart26$5,805
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,147
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic25$2,851
Droplet Pen NeedlePen Needle, Diabetic11$1,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$13$222,822162 claims
Novo NordiskOzempic, Novolog$182$123,09498 claims
AstraZenecaFarxiga$46$32,47322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 430 adult health providers in Colorado.

Other adult health in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →